At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Midazolam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Repeat Dosing of Imlunestrant on CYP3A Activity in Healthy Women of Non-childbearing Potential
In Brief
A Phase 1 clinical trial evaluating Midazolam and Imlunestrant for Healthy. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of non-childbearing potential. This study will last up to approximately 6 weeks for each participant including the screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartSep 2022
Primary CompletionNov 2022
TodayJul 2026
First PostedAug 22, 2022
Enrollment StartSep 12, 2022
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.9 years ago
Interventions
Midazolamdrug
Administered orally.
Imlunestrantdrug
Administered orally.